On April 25, 2023 Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, reported that it will discuss the potential of using epigenetic reprogramming to fight disease, including cancer (Press release, Turn Biotechnologies, APR 25, 2023, View Source [SID1234630498]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Mustafa Turkoz, PhD, Turn Bio immunology, will share data showing the company has used its ERA (Epigenetic Reprogramming of Age) technology to enhance T cell performance against tumor cells. The technology is expected to improve the efficacy of CAR-T cell therapies.
Turn Biotechnologies has used its ERA (Epigenetic Reprogramming of Age) technology to enhance T cell performance against tumor cells. The technology is expected to improve the efficacy of CAR-T cell therapies. Data will be shared at the World Oncology Cell Therapy Congress on Wednesday.
The discussion will occur at the World Oncology Cell Therapy Congress being held April 25-26 in Boston.
Presentation details:
Title: "Restoring youthful vigor to cells to fight disease through epigenome reprogramming."
Location: Hyatt Regency Boston, One Avenue De Lafayette, Boston, during the Developing Better TCR-Directed Approaches.
Date and Time: Wednesday, April 26, 2023, at 3 p.m. Eastern Time.
The World Oncology Cell Therapy Congress is the only annual meeting that brings together drug developers, solution providers, and clinicians whose purpose is to deliver safe and effective adoptive cell therapy products to clinical implementation. The meeting is expected to attract hundreds of participants.